Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 7:02 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 7,824 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Acute Disease Clear all

Conditions: Falls (Accidents) in Old Age
Interventions: GAPcare intervention; Behavioral
Lead sponsor: Rhode Island Hospital; Other
Eligibility: 65 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Providence, Rhode Island

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome, Uveal Melanoma
Interventions: BPX-701, Rimiducid; Biological · Drug
Lead sponsor: Bellicum Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 3
States / cities: Denver, Colorado • Portland, Oregon • Nashville, Tennessee

Conditions: Acute Kidney Failure
Interventions: Furosemide; Drug
Lead sponsor: George Washington University; Other
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Parkinson Disease, Parkinsonism
Interventions: Acute intermittent hypercapnic hypoxia (AIHH), Acute intermittent hypercapnic normoxia (AIHN); Other
Lead sponsor: University of Florida; Other
Eligibility: 40 Years to 75 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Gainesville, Florida

Conditions: Chronic Pain Due to Injury, Acute Pain, Depression, Brain Injuries
Interventions: Experimental: Investigate the effects of an exercise intervention on retired APF players; Behavioral
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: GVHD, AML, ALL, MDS, MPN, CMML, Hodgkin Lymphoma, Non Hodgkin Lymphoma, Blood Stem Cell Transplant Failure, Graft Vs Host Disease, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorder, Chronic Myelomonocytic Leukemia, Chemosensitive Hodgkin Lymphoma
Interventions: FLUDARABINE, CYCLOPHOSPHAMIDE, TBI, Melphalan, Sirolimus, Mycophenolate mofetil, RGI-2001; Drug · Radiation
Lead sponsor: Zachariah Michael DeFilipp; Other
Eligibility: 18 Years to 80 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Leukemia, Acute, Myelodysplastic Syndromes, Myelomonocytic Leukemia, Chronic, T-cell Prolymphocytic Leukemia, CML, Myeloproliferative Disorders, Multiple Myeloma, Plasma Cell Leukemia
Interventions: Itacitinib; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 60 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Allergic Conjunctivitis
Interventions: AKF-1; Drug
Lead sponsor: Akorn, Inc.; Industry
Eligibility: 10 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Acute Lymphoblastic Leukemia (ALL)
Interventions: Carfilzomib, Dexamethasone, Mitoxantrone, PEG-asparaginase, Vincristine, Intrathecal (IT) Methotrexate, Intrathecal Triple Therapy (Intrathecal Cytarabine, Hydrocortisone, and Methotrexate), 6-Mercaptopurine, Cyclophosphamide, Cytarabine, Daunorubicin; Drug
Lead sponsor: Amgen; Industry
Eligibility: 1 Month to 21 Years
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 22
States / cities: Oakland, California • Orange, California • Aurora, Colorado + 19 more

Conditions: Advanced Cancer, Delirium
Interventions: Questionnaire; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Atypical Chronic Myeloid Leukemia, Chronic Monocytic Leukemia, Myelofibrosis, Myelodysplastic/Myeloproliferative Neoplasm
Interventions: Hyperbaric oxygen; Drug
Lead sponsor: Omar Aljitawi; Other
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Migraine Headache, Cognitive Impairment
Interventions: Treximet, Migraine rescue medication of choice; Drug
Lead sponsor: Neurological Research Center; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Bennington, Vermont

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Up to 24 Months
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Respiratory Distress Syndrome, Adult, Bronchiolitis Obliterans, Pneumonia
Interventions: etanercept; Drug
Lead sponsor: FDA Office of Orphan Products Development; Federal
Eligibility: 12 Months and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Carotid Artery Diseases
Interventions: CGuard Prime 80cm stent system; Device
Lead sponsor: InspireMD; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 8
States / cities: Sacramento, California • Indianapolis, Indiana • Minneapolis, Minnesota + 5 more

Conditions: Acute Coronary Syndrome, TIA, Stroke, Cardiac Arrest, PTSD
Interventions: Written Exposure Therapy; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Acute Myeloid Leukemia
Interventions: Bleximenib, Cytarabine, Daunorubicin or Idarubicin, Placebo; Drug
Lead sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland; Other
Eligibility: 18 Years and older
Enrollment: 875 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 13
States / cities: Los Angeles, California • San Francisco, California • Orlando, Florida + 10 more

Conditions: Adult Acute Promyelocytic Leukemia (M3), Blastic Phase Chronic Myelogenous Leukemia, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, Relapsing Chronic Myelogenous Leukemia
Interventions: bortezomib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acute Mountain Sickness
Interventions: Prochlorperazine Maleate, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 75 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Evergreen, Colorado

Conditions: Essential Thrombocythemia, Myelofibrosis, Myeloproliferative Neoplasm, Polycythemia Vera, Secondary Acute Myeloid Leukemia
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Liposome-encapsulated Daunorubicin-Cytarabine, Ruxolitinib; Procedure · Drug
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 3
States / cities: Columbus, Ohio • Portland, Oregon • Dallas, Texas

Conditions: Leukemia, Acute Myeloid Leukemia, Lymphoblastic Leukemia in Children
Interventions: Dalbavancin, Fluoroquinolone (either ciprofloxacin or levofloxacin at the discretion of the treating clinician); Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 25 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Aggressive Systemic Mastocytosis (ASM), SM w Assoc Clonal Hema Non-mast Cell Lineage Disease (SM-AHNMD), Mast Cell Leukemia (MCL), Smoldering Systemic Mastocytosis (SSM), Indolent Systemic Mastocytosis (ISM) ISM Subgroup Fully Recruited
Interventions: Interview; Other
Lead sponsor: Adelphi Values LLC; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Migraine
Interventions: Placebo ZNS, ZNS; Drug
Lead sponsor: Impax Laboratories, LLC; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 374 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 47
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 38 more

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Cytarabine, Daunorubicin, Echocardiography Test, Fludarabine, Idarubicin, Multigated Acquisition Scan, Questionnaire Administration, Venetoclax, Device FLT3 Inhibitor; Procedure · Drug · Other + 1 more
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Portland, Oregon

Search by objective public record fields.

GAPcare: The Geriatric Acute & Post-acute Care Coordination Program for Fall Prevention in the Emergency Department

Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma

Protocol to Assess the Severity of Acute Kidney Injury

Cross-System Effects of Acute Intermittent Hypercapnia-Based Interventions in PD

Evaluating the Impact of Focused Muscle Contraction Therapy in Retire APF Players

Haplo Peripheral Blood Sct In GVHD Prevention

Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients

An Evaluation of the Onset and Duration of Action of AKF-1 Ophthalmic Solution in Treating Acute Allergic Conjunctivitis

Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia

Delirium Recall in Advanced Cancer Patients

Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant

Treximet in Acute Migraine Headache: Assessing Cognitive Function

Immune Function of Infants With HIV

Etanercept for Non-Infectious Lung Injury Following Bone Marrow Transplantation

A Single-arm, Pivotal Study to Evaluate Acute Device and Technical Success of the CGuard Prime Carotid Stent System When Used in Conjunction to the ENROUTE Transcarotid Neuroprotection System in Patients Undergoing Carotid Artery Stenting Via the Transcarotid Artery Revascularization Approach

Early Psychological Intervention to Prevent Cardiovascular Event-Induced PTSD (REACH Sub-study)

Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

PS-341 in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia in Blast Phase, or Myelodysplastic Syndrome

Prochlorperazine Maleate Versus Placebo for the Prophylaxis of Acute Mountain Sickness

Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia

Patient-Reported Outcome Questionnaire for Systemic Mastocytosis

Efficacy & Safety Of Zomig Nasal Spray For Acute Migraine Treatment In Subjects 6 To 11 Years, With OLE

Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia